Merck and Ridgeback Report Results for Lagevrio in P-II Studies for the Treatment of COVID-19
Shots:
- The (PANORAMIC) trial evaluates the safety & efficacy of Lagevrio (800mg, BID) + usual care vs usual care in patients (n=25,783) aged ≥50yrs. with COVID-19. The study showed no reduction in hospitalizations & death @28days of randomization whereas the 2EPs was 6days shorter with usual care vs without usual care
- The (Clalit) trial evaluates the real-world effectiveness of Lagevrio in patients (n=19,868) aged ≥65yrs. for the prevention of COVID-19 with results showing a reduction in hospitalization & mortality in patients aged ≥65yrs. along with no evidence of benefit found in patients aged 40-64yrs.
- The (Tg RasH2) study evaluating the carcinogenicity of Lagevrio in transgenic mice receiving molnupiravir (30/100/300mg/kg/day) for 6mos. showed that Lagevrio was not carcinogenic
Ref: Businesswire | Image: Merck
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
